Compounded tirzepatide in 2026: legality, cost, and safety

The short answer: compounded tirzepatide was a product of a drug shortage, and the shortage is over. FDA's final decision that the tirzepatide shortage was resolved came on December 19, 2024, and the grace periods for compounders ended on February 18, 2025 for 503A pharmacies and March 19, 2025 for 503B outsourcing facilities. [1] Since then, a pharmacy may lawfully compound tirzepatide only in narrow, patient-specific cases. [2] For most people the lawful route is the branded drug, and branded cash prices now overlap with what compounded product cost during the shortage.

This guide covers the timeline, the rules, prices, FDA's safety warnings, and how to check a pharmacy. For the parallel story on semaglutide, see what happened to compounded semaglutide, and for the step-by-step prescription process across both drugs, see how to get a compounded GLP-1 prescription.

Why compounded tirzepatide existed: the shortage timeline

While a drug is on FDA's shortage list, the rules that normally stop pharmacies from making copies of an approved drug are relaxed. Tirzepatide injection products went into shortage in 2022 because of demand. [1] The key dates after that:

• October 2, 2024: FDA determined the shortage was resolved.
• October 2024: during litigation over that decision, FDA agreed to reevaluate it.
• December 19, 2024: FDA reaffirmed that the shortage was resolved.
• February 18, 2025: end of the enforcement grace period for 503A pharmacies.
• March 19, 2025: end of the grace period for 503B outsourcing facilities. [1]

Every date is also on the tirzepatide regulatory tracker.

Is compounded tirzepatide legal in 2026?

Only in narrow cases, and the answer depends on the type of compounder.

503A pharmacies are state-licensed pharmacies that compound for individual patients with a prescription. Outside a shortage, federal law bars them from regularly compounding drugs that are essentially copies of a commercially available drug. The exception is a change that the prescriber determines produces a significant difference for that patient. [2] FDA treats a compounded product as essentially a copy when it has the same active ingredient in the same, similar, or easily substituted strength and the same route as the approved drug. It has also said it does not intend to act against a pharmacy that fills four or fewer prescriptions of such a copy in a calendar month. [1]

503B outsourcing facilities register with FDA, follow federal manufacturing standards, and are inspected by FDA. [4] FDA gave them a separate, later deadline because they also may not compound copies of an approved drug once a shortage ends. [1]

In practice, a lawful patient-specific reason looks like an allergy to an inactive ingredient in the branded product or a strength the manufacturer does not make. Adding an ingredient such as a vitamin does not, on its own, show a significant difference for you; the statute turns on what your prescriber determines about you as an individual patient. [2] Cost alone is not a patient-specific clinical need. FDA's April 1, 2026 policy update says a compounded GLP-1 combined with a vitamin may be treated as essentially a copy when the strengths are within 10% of approved products and the route is the same, unless the prescriber documents a real difference for the individual patient. [1] A September 2026 FDA warning letter applied this to tirzepatide and semaglutide vitamin combinations, said high production volume suggested the claimed differences were a pretext, and questioned significant-difference statements picked from preset menus on prescribing platforms. [14]

State law sits on top of federal law. Pharmacy licensing, nonresident shipping, and telehealth rules vary by state; see our state legal guides, such as Texas.

Is compounded tirzepatide the same as Zepbound?

No. Compounded drugs are not FDA approved, and FDA does not review them for safety, effectiveness, or quality before they are sold. [3] Zepbound and Mounjaro are the approved tirzepatide products. Zepbound is approved for weight reduction in adults with obesity or overweight with a weight-related condition, and for moderate to severe obstructive sleep apnea in adults with obesity. [6]

FDA has flagged two specific differences:

• Salt forms. Some compounded tirzepatide may use tirzepatide sodium or tirzepatide acetate, which FDA calls different active ingredients from the one in the approved drugs. [5]
• Marketing. On March 3, 2026, FDA announced warning letters to 30 telehealth companies over false or misleading claims about compounded GLP-1 products, including implying they are the same as, or generic versions of, the approved drugs. [7]

Compounded tirzepatide cost

During the shortage, a peer-reviewed study of 79 websites selling compounded GLP-1 drugs, searched from July to September 2024, found that 57 sold compounded tirzepatide, at a median first-month price of 330 USD and a middle range of 275 to 399 USD. [8] The same study found that many sites described their products with language such as "same active ingredient" as the brand. [8] We have found no current, dated price for lawful routine compounded tirzepatide, because routine compounding is no longer allowed.

Branded prices, checked September 22, 2026:

• Manufacturer self-pay: 299 USD a month at 2.5 mg, 399 at 5 mg, 499 at 7.5 mg, and 699 at 10 mg and above, for Zepbound vials or the KwikPen. [9]
• Refill offer: 449 USD a month for the 7.5 mg to 15 mg KwikPen when each refill is completed on time, through December 31, 2026. [10]
• Commercial insurance with a savings card: as little as 25 USD when the plan covers it. [9]
• Medicare: eligible Part D enrollees can get the Zepbound KwikPen for weight management at a 50 USD monthly copay under the Medicare GLP-1 Bridge, from July 1, 2026, with prior authorization. [11]

The full price table, with list prices and telehealth program fees, is on the tirzepatide cost page.

Compounded tirzepatide safety: adverse events and dosing errors

As of May 31, 2026, FDA had received more than 730 adverse event reports associated with compounded tirzepatide. [5] Because 503A pharmacies are not required to report adverse events to FDA, the real count is likely higher. [5] FDA has also received reports of adverse events that may be linked to dosing errors with compounded tirzepatide, including doses beyond what the approved label describes, with nausea, vomiting, diarrhea, abdominal pain, and constipation among the problems reported. [5]

Part of the risk is the format. The approved label sets a gradual schedule: 2.5 mg once weekly for 4 weeks, then increases in 2.5 mg steps after at least 4 weeks on the current dose, to a maintenance dose of 5, 10, or 15 mg once weekly, with 15 mg the maximum. [6] Branded pens and vials come in fixed strengths that match those steps. Compounded products may come in strengths and concentrations that differ from the label, which leaves more room for mistakes. That schedule is also why "microdosing" claims deserve scrutiny; see microdosing GLP-1s: what the evidence says.

The approved drug has the trial record: in SURMOUNT-1, tirzepatide 15 mg produced a mean weight change of minus 20.9% at 72 weeks versus minus 3.1% on placebo. [12] No compounded product has a trial of its own.

You can search reported adverse events on FDA's FAERS public dashboard, and report a problem with any drug, compounded or branded, through FDA's MedWatch program. [5] [13]

How to check a compounding pharmacy

If your prescriber documents a clinical reason for compounded tirzepatide, check the pharmacy before you fill it:

1. License. Confirm the pharmacy is licensed by the board of pharmacy in your state, including a nonresident license if it ships from elsewhere. FDA's BeSafeRx campaign lists this, a required prescription, and access to a licensed pharmacist as basic signs of a legitimate pharmacy. [15]
2. Type. Ask whether it is a 503A pharmacy or a 503B outsourcing facility, and check that a 503B facility is registered with FDA. [4]
3. Active ingredient. Ask what form of tirzepatide it uses and where it comes from. Salt forms are a red flag. [5]
4. Labels. Walk away from anything labeled "for research use" or "not for human consumption." FDA says those products are sold illegally. [5]

Our provider verification guide explains how we vet listings.

Compounded tirzepatide vs the alternatives

If cost is the issue, compare the branded self-pay price with what you were quoted for compounded product, and ask about insurance for a covered indication such as sleep apnea. If you are choosing between drugs, our semaglutide vs tirzepatide comparison covers the head-to-head data, and the obesity condition page grades every option. Retatrutide is sometimes offered as a next step; it is not approved and cannot be compounded, as our tirzepatide vs retatrutide comparison explains. For the class as a whole, see the GLP-1 hub, and for the difference between the two tirzepatide brands, see Zepbound vs Mounjaro.